| Trajectories of injectable cancer drug costs after launch in the United States N Gordon, SM Stemmer, D Greenberg, DA Goldstein Journal of clinical oncology 36 (4), 319-325, 2018 | 113 | 2018 |
| A phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non–small cell lung cancer DA Goldstein, N Gordon, M Davidescu, M Leshno, CE Steuer, N Patel, ... JNCI: Journal of the National Cancer Institute 109 (11), djx063, 2017 | 98 | 2017 |
| Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma A Moore, M Cohen-Naftaly, A Tobar, Y Kundel, O Benjaminov, M Braun, ... Radiation Oncology 12, 1-8, 2017 | 72 | 2017 |
| Cost effectiveness of nivolumab in advanced renal cell carcinoma M Sarfaty, M Leshno, N Gordon, A Moore, V Neiman, E Rosenbaum, ... European urology 73 (4), 628-634, 2018 | 65 | 2018 |
| Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer M Sarfaty, PS Hall, KKW Chan, K Virik, M Leshno, N Gordon, A Moore, ... European urology 74 (1), 57-62, 2018 | 56 | 2018 |
| Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study N Goldberg, Y Kundel, O Purim, H Bernstine, N Gordon, S Morgenstern, ... Radiation oncology 7 (1), 1-9, 2012 | 38 | 2012 |
| RET fusion lung carcinoma: response to therapy and clinical features in a case series of 14 patients M Sarfaty, A Moore, V Neiman, E Dudnik, M Ilouze, M Gottfried, ... Clinical lung cancer 18 (4), e223-e232, 2017 | 37 | 2017 |
| The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States A Moore, I Stav, RB Den, N Gordon, M Sarfaty, V Neiman, E Rosenbaum, ... Journal of oncology 2019, 2019 | 29 | 2019 |
| Young-onset gastric cancer and Epstein–Barr Virus (EBV)–a major player in the pathogenesis? A Moore, E Hikri, T Goshen-Lago, T Barkan, S Morgenstern, E Brook, ... BMC cancer 20, 1-7, 2020 | 25 | 2020 |
| The cost and value of cancer drugs–are new innovations outpacing our ability to pay? DA Goldstein, SM Stemmer, N Gordon Israel Journal of Health Policy Research 5, 1-4, 2016 | 25 | 2016 |
| The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: Mature … B Brenner, O Purim, N Gordon, T Goshen–Lago, E Idelevich, H Kashtan, ... Radiotherapy and Oncology 134, 74-80, 2019 | 15 | 2019 |
| PafR, a novel transcription regulator, is important for pathogenesis in uropathogenic Escherichia coli M Baum, M Watad, SN Smith, CJ Alteri, N Gordon, I Rosenshine, ... Infection and immunity 82 (10), 4241-4252, 2014 | 14 | 2014 |
| Next‐generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage—Multicenter experience A Moore, Y Bar, C Maurice‐Dror, I Ospovat, M Sarfaty, Y Korzets, ... Head & Neck 42 (4), 599-607, 2020 | 12 | 2020 |
| The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: a single-institution experience IB Aharon, O Purim, Y Kundel, R Brenner, N Gordon, A Sulkes, B Brenner Anti-cancer drugs 23 (3), 313-320, 2012 | 12 | 2012 |
| A real-world analysis of cancer drug wastage due to oversized vials O Liran, J Prus, N Gordon, V Almog, T Gruenewald, DA Goldstein Journal of the American Pharmacists Association 58 (6), 643-646, 2018 | 11 | 2018 |
| Brain metastasis in gastroesophageal adenocarcinoma and HER2 status D Limon, O Gal, N Gordon, L Katz, G Perl, O Purim, L Amit, SM Stemmer, ... Journal of neuro-oncology 138 (2), 315-320, 2018 | 11 | 2018 |
| ReCAP: perspectives of patients, caregivers, and medical staff on greetings in oncology practice: a prospective survey D Limon, S Perry, T Granot, N Gordon, N Stemmer, SM Stemmer, D Limon, ... Journal of oncology practice 12 (2), 170-171, 2016 | 11 | 2016 |
| Early postoperative 18F-FDG PET/CT in high-risk stage III colorectal cancer N Wasserberg, O Purim, V Bard, Y Kundel, N Gordon, D Groshar, ... Clinical nuclear medicine 40 (4), e222-e227, 2015 | 10 | 2015 |
| Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience A Moore, Y Bar, C Maurice-Dror, I Finkel, H Goldvaser, E Dudnik, ... Medicine 100 (25), e26388, 2021 | 8 | 2021 |
| A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer. DA Goldstein, N Gordon, M Davidescu, M Leshno, CE Steuer, N Patel, ... Journal of Clinical Oncology 35 (15_suppl), 9013-9013, 2017 | 8 | 2017 |
Stemmer SMRabin Medical CenterVerified email at post.tau.ac.il
